BRIEF published on 06/03/2024 at 07:35, 2 years ago GenSight Biologics Welcomes William Monteith to the Board of Directors Board Of Directors Nomination GenSight Biologics William Monteith Gene Therapies
PRESS RELEASE published on 06/03/2024 at 07:30, 2 years ago Informations privilégiées / Autres communiqués GenSight Biologics nomme William Monteith à son Conseil d'administration. Monteith apportera son expertise en fabrication de thérapies géniques pour soutenir les progrès de l'entreprise Conseil D'administration Fabrication GenSight Biologics Thérapies Géniques William Monteith
BRIEF published on 05/23/2024 at 11:40, 2 years ago Franchissement de seuils pour GENSIGHT BIOLOGICS S.A. Actions Franchissement De Seuils Bons De Souscription GenSight Biologics Armistice Capital
BRIEF published on 05/23/2024 at 11:40, 2 years ago Crossing thresholds for GENSIGHT BIOLOGICS SA Actions Crossing Thresholds GenSight Biologics Armistice Capital Subscription Warrants
PRESS RELEASE published on 05/23/2024 at 11:35, 2 years ago Franchissement de seuils Déclaration de franchissement de seuils par Armistice Capital, LLC concernant GENSIGHT BIOLOGICS S.A. sur Euronext Paris Euronext Paris Franchissement De Seuils Armistice Capital LLC GENSIGHT BIOLOGICS SA Déclaration Régularisation
BRIEF published on 05/07/2024 at 19:34, 2 years 1 month ago GenSight Biologics Announces Availability of Prospectus for New Shares Listing on Euronext Paris Euronext Paris Capital Increase Gene Therapy Prospectus GenSight Biologics
BRIEF published on 05/07/2024 at 19:34, 2 years 1 month ago GenSight Biologics annonce la mise à disposition d'un prospectus pour la cotation de nouvelles actions sur Euronext Paris Euronext Paris Augmentation De Capital Thérapie Génique Prospectus Produits Biologiques GenSight
PRESS RELEASE published on 05/07/2024 at 19:29, 2 years 1 month ago Terms of availability of prospectuses GenSight Biologics announces availability of listing prospectus for new shares on Euronext Paris. The prospectus approved by AMF includes universal registration document, securities note, and summary Euronext Paris New Shares AMF Approval GenSight Biologics Listing Prospectus
PRESS RELEASE published on 05/07/2024 at 19:29, 2 years 1 month ago Modalités de mise à disposition de prospectus GenSight Biologics annonce la mise à disposition d'un prospectus pour l'admission d'actions nouvelles sur Euronext Paris. La société spécialisée dans les thérapies géniques pour les maladies neurodégénératives informe sur le processus Euronext Paris Prospectus GenSight Biologics Thérapies Géniques Maladies Neurodégénératives
Published on 06/22/2026 at 21:05, 55 minutes ago RUM Announces Voting Results From Annual General Meeting of Shareholders
Published on 06/22/2026 at 19:45, 2 hours 15 minutes ago Trans Canada Gold Appoints Paradigm Drilling Ltd. for Drilling at the Harrison Lake District Scale Gold Project, Drilling to Commence Shortly
Published on 06/22/2026 at 15:58, 6 hours 2 minutes ago Metallic Minerals Closes Upsized C$10.3 Million Bought Deal LIFE Private Placement
Published on 06/22/2026 at 15:30, 6 hours 30 minutes ago NanoViricides Has Shipped NV-387 Oral Gummies Drug Product for Phase II Clinical Trial to DR Congo
Published on 06/22/2026 at 15:00, 7 hours ago Jaguar Health Announces Plan to Explore Strategic Alternatives Aligned with Targeted NDA Filing for Rare Disease Intestinal Failure Program
Published on 06/22/2026 at 21:07, 53 minutes ago EQS-Adhoc: RWE Aktiengesellschaft: RWE sets placement price for shares from capital measure and raises gross proceeds of 4 billion EUR
Published on 06/22/2026 at 20:50, 1 hour 10 minutes ago Ethlabs, Founded by Former Ethereum Foundation Contributors and Funded by Bitmine, Sharplink and Joe Lubin, Launches to Accelerate Ethereum's Institutional Supercycle
Published on 06/22/2026 at 20:32, 1 hour 28 minutes ago EQS-Adhoc: Deutsche Konsum Real Estate AG: Daniel Löhken appointed Chief Executive Officer of the Company and Dr Kai Gregor Klinger appointed new Chairman of the Supervisory Board
Published on 06/22/2026 at 19:27, 2 hours 33 minutes ago Fuller, Smith & Turner PLC: Director/PDMR Shareholdings
Published on 06/22/2026 at 18:54, 3 hours 6 minutes ago EQS-Adhoc: Brenntag SE publishes preliminary operating EBITDA for the second quarter of 2026 and increases its guidance for the financial year 2026
Published on 06/22/2026 at 18:00, 4 hours ago GUILLEMOT CORPORATION : DECES DE M. CLAUDE GUILLEMOT, Président du Groupe GUILLEMOT CORPORATION
